Company: CRNX
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0001193125-25-175498
Chunk: 0

Company: Crinetics Pharmaceuticals, Inc.
Filing Date: 2025-08-07
Form: 10-Q
Item: Part I, Item 1
Chunk 0
---
Crinetics Pharmaceuticals, Inc. 

Condensed Consolidated Balance Sheets

(in thousands, except per share data)  

     June 30,

     December 31,

     2025

     2024

     (Unaudited)

     Assets

     Current assets:

     Cash and cash equivalents
      
     $
     53,726

     $
     264,545

     Restricted cash

     500

     500

     Investment securities, amortized cost of $1,140,985 at June 30, 2025 and $1,088,561 at December 31, 2024

     1,142,634

     1,089,524

     Prepaid expenses and other current assets

     20,404

     20,819

     Total current assets

     1,217,264

     1,375,388

     Property and equipment, net

     14,670

     12,068

     Operating lease right-of-use assets

     41,902

     43,507

     Restricted cash, net of current portion

     800

     800

     Prepaid expenses and other assets, net of current portion

     14,938

     2,829

     Total assets
      
     $
     1,289,574

     $
     1,434,592

     Liabilities and Stockholders’ Equity

     Current liabilities:

     Accounts payable and accrued expenses
      
     $
     38,086

     $
     21,469

     Accrued compensation and related expenses

     21,796

     28,887

     Deferred revenue

     1,904

     2,176

     Operating lease liabilities

     6,610

     7,152

     Total current liabilities

     68,396

     59,684

     Operating lease liabilities, non-current

     43,326

     44,570

     Deferred revenue, non-current

     3,992

     4,704

     Other liabilities

     2,334

     829

     Total liabilities

     118,048

     109,787

     Commitments and contingencies (Note 6)

     Stockholders’ equity:

     Preferred stock, $0.001 par; 10,000 shares authorized;